MedTrace Logo

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

NCT00313170 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2020-01-06

Study results available
· View outcomes & findings →

Summary

This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.

Conditions

Interventions

DRUG

Fulvestrant

intramuscular injection 250 mg \& 500 mg

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Breast Cancer Established Brands Team Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
130 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-30
Primary Completion
2008-06-13
Completion
2019-03-13

Countries

  • Belgium
  • Canada
  • Czechia
  • France
  • Hungary
  • Poland
  • Romania
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00313170 on ClinicalTrials.gov